KSQ Therapeutics is a biotech company based in Cambridge, Massachusetts that focuses on developing novel drugs using their proprietary CRISPRomics platform. By understanding the function of each human gene in multiple diseases, they can identify and validate high-confidence drug targets. This approach allows them to prioritize the development of medicines with the greatest potential impact on patients' lives. Currently, they are advancing a pipeline of oncology and immunology drug candidates.